Open‐label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease
Identifieur interne : 002B43 ( Istex/Corpus ); précédent : 002B42; suivant : 002B44Open‐label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease
Auteurs : Theresa A. Zesiewicz ; Kelly L. Sullivan ; Robert A. Hauser ; Juan Sanchez-RamosSource :
- Movement Disorders [ 0885-3185 ] ; 2006-11.
English descriptors
- KwdEn :
Abstract
The objective of this study is to evaluate the tolerability and preliminary efficacy of levetiracetam (LEV) in reducing chorea in Huntington's disease (HD) patients in a prospective open‐label pilot study. Nine HD patients with chorea were treated with LEV in doses up to 3,000 mg/day for up to 48 days. The primary endpoint measure was the Unified Huntington's Disease Rating Scale (UHDRS) chorea subscore. The mean dose (±SD) of LEV at endpoint was 2,583.3 ± 1,020.6 mg/day. Mean UHDRS chorea score decreased from 12.6 ± 3.0 at baseline to 6.7 ± 4.3 at endpoint (P = 0.01). There was no significant change in UHDRS total motor scores (38.8 ± 11.4 at baseline and 33.6 ± 26.7 at endpoint; P = 0.24). Somnolence contributed to a 33% drop‐out rate, and 3 patients developed Parkinsonism. Results of this open label study suggest that LEV may be efficacious in reducing chorea in HD patients. © 2006 Movement Disorder Society
Url:
DOI: 10.1002/mds.21061
Links to Exploration step
ISTEX:298284E6EA71525F8E1A0FAFDA76BECAF0FCEE4BLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Open‐label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease</title>
<author><name sortKey="Zesiewicz, Theresa A" sort="Zesiewicz, Theresa A" uniqKey="Zesiewicz T" first="Theresa A." last="Zesiewicz">Theresa A. Zesiewicz</name>
<affiliation><mods:affiliation>Parkinson's Disease and Movement Disorders Center and Department of Neurology, University of South Florida, Tampa, Florida, USA</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>James A. Haley Veterans Administration Hospital, University of South Florida, Tampa, Florida, USA</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Sullivan, Kelly L" sort="Sullivan, Kelly L" uniqKey="Sullivan K" first="Kelly L." last="Sullivan">Kelly L. Sullivan</name>
<affiliation><mods:affiliation>Parkinson's Disease and Movement Disorders Center and Department of Neurology, University of South Florida, Tampa, Florida, USA</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
<affiliation><mods:affiliation>Parkinson's Disease and Movement Disorders Center and Department of Neurology, University of South Florida, Tampa, Florida, USA</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>Department of Pharmacology and Experimental Therapeutics, University of South Florida, Tampa, Florida, USA</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Sanchez Amos, Juan" sort="Sanchez Amos, Juan" uniqKey="Sanchez Amos J" first="Juan" last="Sanchez-Ramos">Juan Sanchez-Ramos</name>
<affiliation><mods:affiliation>Parkinson's Disease and Movement Disorders Center and Department of Neurology, University of South Florida, Tampa, Florida, USA</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>James A. Haley Veterans Administration Hospital, University of South Florida, Tampa, Florida, USA</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</mods:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:298284E6EA71525F8E1A0FAFDA76BECAF0FCEE4B</idno>
<date when="2006" year="2006">2006</date>
<idno type="doi">10.1002/mds.21061</idno>
<idno type="url">https://api.istex.fr/document/298284E6EA71525F8E1A0FAFDA76BECAF0FCEE4B/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">002B43</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Open‐label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease</title>
<author><name sortKey="Zesiewicz, Theresa A" sort="Zesiewicz, Theresa A" uniqKey="Zesiewicz T" first="Theresa A." last="Zesiewicz">Theresa A. Zesiewicz</name>
<affiliation><mods:affiliation>Parkinson's Disease and Movement Disorders Center and Department of Neurology, University of South Florida, Tampa, Florida, USA</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>James A. Haley Veterans Administration Hospital, University of South Florida, Tampa, Florida, USA</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Sullivan, Kelly L" sort="Sullivan, Kelly L" uniqKey="Sullivan K" first="Kelly L." last="Sullivan">Kelly L. Sullivan</name>
<affiliation><mods:affiliation>Parkinson's Disease and Movement Disorders Center and Department of Neurology, University of South Florida, Tampa, Florida, USA</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
<affiliation><mods:affiliation>Parkinson's Disease and Movement Disorders Center and Department of Neurology, University of South Florida, Tampa, Florida, USA</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>Department of Pharmacology and Experimental Therapeutics, University of South Florida, Tampa, Florida, USA</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Sanchez Amos, Juan" sort="Sanchez Amos, Juan" uniqKey="Sanchez Amos J" first="Juan" last="Sanchez-Ramos">Juan Sanchez-Ramos</name>
<affiliation><mods:affiliation>Parkinson's Disease and Movement Disorders Center and Department of Neurology, University of South Florida, Tampa, Florida, USA</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>James A. Haley Veterans Administration Hospital, University of South Florida, Tampa, Florida, USA</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</mods:affiliation>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2006-11">2006-11</date>
<biblScope unit="vol">21</biblScope>
<biblScope unit="issue">11</biblScope>
<biblScope unit="page" from="1998">1998</biblScope>
<biblScope unit="page" to="2001">2001</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">298284E6EA71525F8E1A0FAFDA76BECAF0FCEE4B</idno>
<idno type="DOI">10.1002/mds.21061</idno>
<idno type="ArticleID">MDS21061</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Huntington's disease</term>
<term>Keppra</term>
<term>chorea</term>
<term>levetiracetam</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The objective of this study is to evaluate the tolerability and preliminary efficacy of levetiracetam (LEV) in reducing chorea in Huntington's disease (HD) patients in a prospective open‐label pilot study. Nine HD patients with chorea were treated with LEV in doses up to 3,000 mg/day for up to 48 days. The primary endpoint measure was the Unified Huntington's Disease Rating Scale (UHDRS) chorea subscore. The mean dose (±SD) of LEV at endpoint was 2,583.3 ± 1,020.6 mg/day. Mean UHDRS chorea score decreased from 12.6 ± 3.0 at baseline to 6.7 ± 4.3 at endpoint (P = 0.01). There was no significant change in UHDRS total motor scores (38.8 ± 11.4 at baseline and 33.6 ± 26.7 at endpoint; P = 0.24). Somnolence contributed to a 33% drop‐out rate, and 3 patients developed Parkinsonism. Results of this open label study suggest that LEV may be efficacious in reducing chorea in HD patients. © 2006 Movement Disorder Society</div>
</front>
</TEI>
<istex><corpusName>wiley</corpusName>
<author><json:item><name>Theresa A. Zesiewicz MD, FAAN</name>
<affiliations><json:string>Parkinson's Disease and Movement Disorders Center and Department of Neurology, University of South Florida, Tampa, Florida, USA</json:string>
<json:string>James A. Haley Veterans Administration Hospital, University of South Florida, Tampa, Florida, USA</json:string>
<json:string>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</json:string>
</affiliations>
</json:item>
<json:item><name>Kelly L. Sullivan MSPH</name>
<affiliations><json:string>Parkinson's Disease and Movement Disorders Center and Department of Neurology, University of South Florida, Tampa, Florida, USA</json:string>
<json:string>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</json:string>
</affiliations>
</json:item>
<json:item><name>Robert A. Hauser MD, FAAN</name>
<affiliations><json:string>Parkinson's Disease and Movement Disorders Center and Department of Neurology, University of South Florida, Tampa, Florida, USA</json:string>
<json:string>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</json:string>
<json:string>Department of Pharmacology and Experimental Therapeutics, University of South Florida, Tampa, Florida, USA</json:string>
</affiliations>
</json:item>
<json:item><name>Juan Sanchez‐Ramos MD, PhD</name>
<affiliations><json:string>Parkinson's Disease and Movement Disorders Center and Department of Neurology, University of South Florida, Tampa, Florida, USA</json:string>
<json:string>James A. Haley Veterans Administration Hospital, University of South Florida, Tampa, Florida, USA</json:string>
<json:string>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</json:string>
</affiliations>
</json:item>
</author>
<subject><json:item><lang><json:string>eng</json:string>
</lang>
<value>levetiracetam</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>Keppra</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>chorea</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>Huntington's disease</value>
</json:item>
</subject>
<language><json:string>eng</json:string>
</language>
<abstract>The objective of this study is to evaluate the tolerability and preliminary efficacy of levetiracetam (LEV) in reducing chorea in Huntington's disease (HD) patients in a prospective open‐label pilot study. Nine HD patients with chorea were treated with LEV in doses up to 3,000 mg/day for up to 48 days. The primary endpoint measure was the Unified Huntington's Disease Rating Scale (UHDRS) chorea subscore. The mean dose (±SD) of LEV at endpoint was 2,583.3 ± 1,020.6 mg/day. Mean UHDRS chorea score decreased from 12.6 ± 3.0 at baseline to 6.7 ± 4.3 at endpoint (P = 0.01). There was no significant change in UHDRS total motor scores (38.8 ± 11.4 at baseline and 33.6 ± 26.7 at endpoint; P = 0.24). Somnolence contributed to a 33% drop‐out rate, and 3 patients developed Parkinsonism. Results of this open label study suggest that LEV may be efficacious in reducing chorea in HD patients. © 2006 Movement Disorder Society</abstract>
<qualityIndicators><score>4.642</score>
<pdfVersion>1.3</pdfVersion>
<pdfPageSize>594 x 792 pts</pdfPageSize>
<refBibsNative>true</refBibsNative>
<abstractCharCount>923</abstractCharCount>
<pdfWordCount>2770</pdfWordCount>
<pdfCharCount>17819</pdfCharCount>
<pdfPageCount>4</pdfPageCount>
<abstractWordCount>156</abstractWordCount>
</qualityIndicators>
<title>Open‐label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease</title>
<genre><json:string>Serial article</json:string>
</genre>
<host><volume>21</volume>
<pages><total>3</total>
<last>2001</last>
<first>1998</first>
</pages>
<issn><json:string>0885-3185</json:string>
</issn>
<issue>11</issue>
<subject><json:item><value>Brief Report</value>
</json:item>
</subject>
<genre></genre>
<language><json:string>unknown</json:string>
</language>
<title>Movement Disorders</title>
<doi><json:string>10.1002/(ISSN)1531-8257</json:string>
</doi>
</host>
<publicationDate>2006</publicationDate>
<copyrightDate>2006</copyrightDate>
<doi><json:string>10.1002/mds.21061</json:string>
</doi>
<id>298284E6EA71525F8E1A0FAFDA76BECAF0FCEE4B</id>
<fulltext><json:item><original>true</original>
<mimetype>application/pdf</mimetype>
<extension>pdf</extension>
<uri>https://api.istex.fr/document/298284E6EA71525F8E1A0FAFDA76BECAF0FCEE4B/fulltext/pdf</uri>
</json:item>
<json:item><original>false</original>
<mimetype>application/zip</mimetype>
<extension>zip</extension>
<uri>https://api.istex.fr/document/298284E6EA71525F8E1A0FAFDA76BECAF0FCEE4B/fulltext/zip</uri>
</json:item>
<istex:fulltextTEI uri="https://api.istex.fr/document/298284E6EA71525F8E1A0FAFDA76BECAF0FCEE4B/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Open‐label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease</title>
</titleStmt>
<publicationStmt><authority>ISTEX</authority>
<publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<availability><p>Wiley Subscription Services, Inc., A Wiley Company</p>
</availability>
<date>2006</date>
</publicationStmt>
<sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Open‐label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease</title>
<author><persName><forename type="first">Theresa A.</forename>
<surname>Zesiewicz</surname>
<roleName type="degree">MD, FAAN</roleName>
</persName>
<note type="correspondence"><p>Correspondence: University of South Florida, 12901 Bruce B. Downs Blvd., MDC Box 55, Tampa, Florida 33612</p>
</note>
<affiliation>Parkinson's Disease and Movement Disorders Center and Department of Neurology, University of South Florida, Tampa, Florida, USA</affiliation>
<affiliation>James A. Haley Veterans Administration Hospital, University of South Florida, Tampa, Florida, USA</affiliation>
<affiliation>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</affiliation>
</author>
<author><persName><forename type="first">Kelly L.</forename>
<surname>Sullivan</surname>
<roleName type="degree">MSPH</roleName>
</persName>
<affiliation>Parkinson's Disease and Movement Disorders Center and Department of Neurology, University of South Florida, Tampa, Florida, USA</affiliation>
<affiliation>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</affiliation>
</author>
<author><persName><forename type="first">Robert A.</forename>
<surname>Hauser</surname>
<roleName type="degree">MD, FAAN</roleName>
</persName>
<affiliation>Parkinson's Disease and Movement Disorders Center and Department of Neurology, University of South Florida, Tampa, Florida, USA</affiliation>
<affiliation>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</affiliation>
<affiliation>Department of Pharmacology and Experimental Therapeutics, University of South Florida, Tampa, Florida, USA</affiliation>
</author>
<author><persName><forename type="first">Juan</forename>
<surname>Sanchez‐Ramos</surname>
<roleName type="degree">MD, PhD</roleName>
</persName>
<affiliation>Parkinson's Disease and Movement Disorders Center and Department of Neurology, University of South Florida, Tampa, Florida, USA</affiliation>
<affiliation>James A. Haley Veterans Administration Hospital, University of South Florida, Tampa, Florida, USA</affiliation>
<affiliation>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</affiliation>
</author>
</analytic>
<monogr><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="pISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<idno type="DOI">10.1002/(ISSN)1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2006-11"></date>
<biblScope unit="vol">21</biblScope>
<biblScope unit="issue">11</biblScope>
<biblScope unit="page" from="1998">1998</biblScope>
<biblScope unit="page" to="2001">2001</biblScope>
</imprint>
</monogr>
<idno type="istex">298284E6EA71525F8E1A0FAFDA76BECAF0FCEE4B</idno>
<idno type="DOI">10.1002/mds.21061</idno>
<idno type="ArticleID">MDS21061</idno>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><creation><date>2006</date>
</creation>
<langUsage><language ident="en">en</language>
</langUsage>
<abstract xml:lang="en"><p>The objective of this study is to evaluate the tolerability and preliminary efficacy of levetiracetam (LEV) in reducing chorea in Huntington's disease (HD) patients in a prospective open‐label pilot study. Nine HD patients with chorea were treated with LEV in doses up to 3,000 mg/day for up to 48 days. The primary endpoint measure was the Unified Huntington's Disease Rating Scale (UHDRS) chorea subscore. The mean dose (±SD) of LEV at endpoint was 2,583.3 ± 1,020.6 mg/day. Mean UHDRS chorea score decreased from 12.6 ± 3.0 at baseline to 6.7 ± 4.3 at endpoint (P = 0.01). There was no significant change in UHDRS total motor scores (38.8 ± 11.4 at baseline and 33.6 ± 26.7 at endpoint; P = 0.24). Somnolence contributed to a 33% drop‐out rate, and 3 patients developed Parkinsonism. Results of this open label study suggest that LEV may be efficacious in reducing chorea in HD patients. © 2006 Movement Disorder Society</p>
</abstract>
<textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head>
<item><term>levetiracetam</term>
</item>
<item><term>Keppra</term>
</item>
<item><term>chorea</term>
</item>
<item><term>Huntington's disease</term>
</item>
</list>
</keywords>
</textClass>
<textClass><keywords scheme="Journal Subject"><list><head>Article category</head>
<item><term>Brief Report</term>
</item>
</list>
</keywords>
</textClass>
</profileDesc>
<revisionDesc><change when="2005-11-21">Received</change>
<change when="2006-04-18">Registration</change>
<change when="2006-11">Published</change>
</revisionDesc>
</teiHeader>
</istex:fulltextTEI>
<json:item><original>false</original>
<mimetype>text/plain</mimetype>
<extension>txt</extension>
<uri>https://api.istex.fr/document/298284E6EA71525F8E1A0FAFDA76BECAF0FCEE4B/fulltext/txt</uri>
</json:item>
</fulltext>
<metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration>
<istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName>
<publisherLoc>Hoboken</publisherLoc>
</publisherInfo>
<doi registered="yes">10.1002/(ISSN)1531-8257</doi>
<issn type="print">0885-3185</issn>
<issn type="electronic">1531-8257</issn>
<idGroup><id type="product" value="MDS"></id>
</idGroup>
<titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title>
<title type="subtitle">Official Journal of the Movement Disorder Society</title>
<title type="short">Mov. Disord.</title>
</titleGroup>
</publicationMeta>
<publicationMeta level="part" position="110"><doi origin="wiley" registered="yes">10.1002/mds.v21:11</doi>
<numberingGroup><numbering type="journalVolume" number="21">21</numbering>
<numbering type="journalIssue">11</numbering>
</numberingGroup>
<coverDate startDate="2006-11">November 2006</coverDate>
</publicationMeta>
<publicationMeta level="unit" type="shortCommunication" position="330" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.21061</doi>
<idGroup><id type="unit" value="MDS21061"></id>
</idGroup>
<countGroup><count type="pageTotal" number="3"></count>
</countGroup>
<titleGroup><title type="articleCategory">Brief Report</title>
<title type="tocHeading1">Brief Reports</title>
</titleGroup>
<copyright ownership="thirdParty">Copyright © 2006 Movement Disorder Society</copyright>
<eventGroup><event type="manuscriptReceived" date="2005-11-21"></event>
<event type="manuscriptRevised" date="2006-02-15"></event>
<event type="manuscriptAccepted" date="2006-04-18"></event>
<event type="publishedOnlineEarlyUnpaginated" date="2006-08-28"></event>
<event type="firstOnline" date="2006-08-28"></event>
<event type="publishedOnlineFinalForm" date="2006-11-08"></event>
<event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:FullText result:FullText" date="2010-03-09"></event>
<event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event>
<event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event>
</eventGroup>
<numberingGroup><numbering type="pageFirst">1998</numbering>
<numbering type="pageLast">2001</numbering>
</numberingGroup>
<correspondenceTo>University of South Florida, 12901 Bruce B. Downs Blvd., MDC Box 55, Tampa, Florida 33612</correspondenceTo>
<linkGroup><link type="toTypesetVersion" href="file:MDS.MDS21061.pdf"></link>
</linkGroup>
</publicationMeta>
<contentMeta><countGroup><count type="figureTotal" number="0"></count>
<count type="tableTotal" number="1"></count>
<count type="referenceTotal" number="13"></count>
<count type="wordTotal" number="1870"></count>
</countGroup>
<titleGroup><title type="main" xml:lang="en">Open‐label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease</title>
<title type="short" xml:lang="en">LEV and Chorea Reduction in HD</title>
</titleGroup>
<creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1 #af2 #af3" corresponding="yes"><personName><givenNames>Theresa A.</givenNames>
<familyName>Zesiewicz</familyName>
<degrees>MD, FAAN</degrees>
</personName>
<contactDetails><email>tzesiewi@hsc.usf.edu</email>
</contactDetails>
</creator>
<creator xml:id="au2" creatorRole="author" affiliationRef="#af1 #af3"><personName><givenNames>Kelly L.</givenNames>
<familyName>Sullivan</familyName>
<degrees>MSPH</degrees>
</personName>
</creator>
<creator xml:id="au3" creatorRole="author" affiliationRef="#af1 #af3 #af4"><personName><givenNames>Robert A.</givenNames>
<familyName>Hauser</familyName>
<degrees>MD, FAAN</degrees>
</personName>
</creator>
<creator xml:id="au4" creatorRole="author" affiliationRef="#af1 #af2 #af3"><personName><givenNames>Juan</givenNames>
<familyName>Sanchez‐Ramos</familyName>
<degrees>MD, PhD</degrees>
</personName>
</creator>
</creators>
<affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Parkinson's Disease and Movement Disorders Center and Department of Neurology, University of South Florida, Tampa, Florida, USA</unparsedAffiliation>
</affiliation>
<affiliation xml:id="af2" countryCode="US" type="organization"><unparsedAffiliation>James A. Haley Veterans Administration Hospital, University of South Florida, Tampa, Florida, USA</unparsedAffiliation>
</affiliation>
<affiliation xml:id="af3" countryCode="US" type="organization"><unparsedAffiliation>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</unparsedAffiliation>
</affiliation>
<affiliation xml:id="af4" countryCode="US" type="organization"><unparsedAffiliation>Department of Pharmacology and Experimental Therapeutics, University of South Florida, Tampa, Florida, USA</unparsedAffiliation>
</affiliation>
</affiliationGroup>
<keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">levetiracetam</keyword>
<keyword xml:id="kwd2">Keppra</keyword>
<keyword xml:id="kwd3">chorea</keyword>
<keyword xml:id="kwd4">Huntington's disease</keyword>
</keywordGroup>
<abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title>
<p>The objective of this study is to evaluate the tolerability and preliminary efficacy of levetiracetam (LEV) in reducing chorea in Huntington's disease (HD) patients in a prospective open‐label pilot study. Nine HD patients with chorea were treated with LEV in doses up to 3,000 mg/day for up to 48 days. The primary endpoint measure was the Unified Huntington's Disease Rating Scale (UHDRS) chorea subscore. The mean dose (±SD) of LEV at endpoint was 2,583.3 ± 1,020.6 mg/day. Mean UHDRS chorea score decreased from 12.6 ± 3.0 at baseline to 6.7 ± 4.3 at endpoint (<i>P</i>
= 0.01). There was no significant change in UHDRS total motor scores (38.8 ± 11.4 at baseline and 33.6 ± 26.7 at endpoint; <i>P</i>
= 0.24). Somnolence contributed to a 33% drop‐out rate, and 3 patients developed Parkinsonism. Results of this open label study suggest that LEV may be efficacious in reducing chorea in HD patients. © 2006 Movement Disorder Society</p>
</abstract>
</abstractGroup>
</contentMeta>
</header>
</component>
</istex:document>
</istex:metadataXml>
<!--Version 0.6 générée le 4-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Open‐label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease</title>
</titleInfo>
<titleInfo type="abbreviated" lang="en"><title>LEV and Chorea Reduction in HD</title>
</titleInfo>
<titleInfo type="alternative" contentType="CDATA" lang="en"><title>Open‐label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease</title>
</titleInfo>
<name type="personal"><namePart type="given">Theresa A.</namePart>
<namePart type="family">Zesiewicz</namePart>
<namePart type="termsOfAddress">MD, FAAN</namePart>
<affiliation>Parkinson's Disease and Movement Disorders Center and Department of Neurology, University of South Florida, Tampa, Florida, USA</affiliation>
<affiliation>James A. Haley Veterans Administration Hospital, University of South Florida, Tampa, Florida, USA</affiliation>
<affiliation>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</affiliation>
<description>Correspondence: University of South Florida, 12901 Bruce B. Downs Blvd., MDC Box 55, Tampa, Florida 33612</description>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Kelly L.</namePart>
<namePart type="family">Sullivan</namePart>
<namePart type="termsOfAddress">MSPH</namePart>
<affiliation>Parkinson's Disease and Movement Disorders Center and Department of Neurology, University of South Florida, Tampa, Florida, USA</affiliation>
<affiliation>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Robert A.</namePart>
<namePart type="family">Hauser</namePart>
<namePart type="termsOfAddress">MD, FAAN</namePart>
<affiliation>Parkinson's Disease and Movement Disorders Center and Department of Neurology, University of South Florida, Tampa, Florida, USA</affiliation>
<affiliation>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</affiliation>
<affiliation>Department of Pharmacology and Experimental Therapeutics, University of South Florida, Tampa, Florida, USA</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Juan</namePart>
<namePart type="family">Sanchez‐Ramos</namePart>
<namePart type="termsOfAddress">MD, PhD</namePart>
<affiliation>Parkinson's Disease and Movement Disorders Center and Department of Neurology, University of South Florida, Tampa, Florida, USA</affiliation>
<affiliation>James A. Haley Veterans Administration Hospital, University of South Florida, Tampa, Florida, USA</affiliation>
<affiliation>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<typeOfResource>text</typeOfResource>
<genre authority="originalCategForm">shortCommunication</genre>
<originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<place><placeTerm type="text">Hoboken</placeTerm>
</place>
<dateIssued encoding="w3cdtf">2006-11</dateIssued>
<dateCaptured encoding="w3cdtf">2005-11-21</dateCaptured>
<dateValid encoding="w3cdtf">2006-04-18</dateValid>
<copyrightDate encoding="w3cdtf">2006</copyrightDate>
</originInfo>
<language><languageTerm type="code" authority="rfc3066">en</languageTerm>
<languageTerm type="code" authority="iso639-2b">eng</languageTerm>
</language>
<physicalDescription><internetMediaType>text/html</internetMediaType>
<extent unit="tables">1</extent>
<extent unit="references">13</extent>
<extent unit="words">1870</extent>
</physicalDescription>
<abstract lang="en">The objective of this study is to evaluate the tolerability and preliminary efficacy of levetiracetam (LEV) in reducing chorea in Huntington's disease (HD) patients in a prospective open‐label pilot study. Nine HD patients with chorea were treated with LEV in doses up to 3,000 mg/day for up to 48 days. The primary endpoint measure was the Unified Huntington's Disease Rating Scale (UHDRS) chorea subscore. The mean dose (±SD) of LEV at endpoint was 2,583.3 ± 1,020.6 mg/day. Mean UHDRS chorea score decreased from 12.6 ± 3.0 at baseline to 6.7 ± 4.3 at endpoint (P = 0.01). There was no significant change in UHDRS total motor scores (38.8 ± 11.4 at baseline and 33.6 ± 26.7 at endpoint; P = 0.24). Somnolence contributed to a 33% drop‐out rate, and 3 patients developed Parkinsonism. Results of this open label study suggest that LEV may be efficacious in reducing chorea in HD patients. © 2006 Movement Disorder Society</abstract>
<subject lang="en"><genre>Keywords</genre>
<topic>levetiracetam</topic>
<topic>Keppra</topic>
<topic>chorea</topic>
<topic>Huntington's disease</topic>
</subject>
<relatedItem type="host"><titleInfo><title>Movement Disorders</title>
<subTitle>Official Journal of the Movement Disorder Society</subTitle>
</titleInfo>
<titleInfo type="abbreviated"><title>Mov. Disord.</title>
</titleInfo>
<subject><genre>article category</genre>
<topic>Brief Report</topic>
</subject>
<identifier type="ISSN">0885-3185</identifier>
<identifier type="eISSN">1531-8257</identifier>
<identifier type="DOI">10.1002/(ISSN)1531-8257</identifier>
<identifier type="PublisherID">MDS</identifier>
<part><date>2006</date>
<detail type="volume"><caption>vol.</caption>
<number>21</number>
</detail>
<detail type="issue"><caption>no.</caption>
<number>11</number>
</detail>
<extent unit="pages"><start>1998</start>
<end>2001</end>
<total>3</total>
</extent>
</part>
</relatedItem>
<identifier type="istex">298284E6EA71525F8E1A0FAFDA76BECAF0FCEE4B</identifier>
<identifier type="DOI">10.1002/mds.21061</identifier>
<identifier type="ArticleID">MDS21061</identifier>
<accessCondition type="use and reproduction" contentType="copyright">Copyright © 2006 Movement Disorder Society</accessCondition>
<recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin>
<recordContentSource>WILEY</recordContentSource>
</recordInfo>
</mods>
</metadata>
<serie></serie>
</istex>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002B43 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 002B43 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Istex |étape= Corpus |type= RBID |clé= ISTEX:298284E6EA71525F8E1A0FAFDA76BECAF0FCEE4B |texte= Open‐label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease }}
This area was generated with Dilib version V0.6.23. |